Delivery Order SPE2DB20D3111-SPE2DB25FA9GW
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count) with a ceiling value of $4,953.94. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count) with a ceiling value of $3,894.90. This competitive award, with no set-aside designation, is issued under a firm fixed-price delivery order contract type and is scheduled for completion by September 3, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $2,848.49 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count supply). This competitively awarded, non-set-aside contract features firm fixed pricing and is scheduled for completion by August 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,942.82 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,123.86 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order was not issued under a set-aside program. The award represents a small-value transaction typical of routine pharmaceutical replenishment orders under the company's larger contract vehicle with DLA. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $1,541.01. This is a firm fixed-price delivery order with no set-aside designation, completed competitively under open procurement requirements. The contract calls for delivery to Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Alfuzosin HCL ER 10 mg tablets (120 count) with a ceiling value of $1,234.86 under a firm fixed price contract type. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, was competitively awarded with no set-aside designation. Performance of this delivery order will be executed from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,367.28 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $2,770.72. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation, indicating it was awarded through open competition. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Alfuzosin ER 10mg (120-count supply) at a firm fixed price of $7,082.16, with completion targeted for September 11, 2025. This non-set-aside competitive award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026....
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA9GWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count packages) valued at $2,733.13. This non-competitive, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services under the company's existing contract vehicle with DLA. This delivery order falls under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime contract running through December 2026 that serves as the company's comprehensive global pharmaceutical support vehicle. AmerisourceBergen is a major pharmaceutical distributor providing critical medical supplies to military and veteran healthcare systems, including the Defense Health Agency and U.S. Coast Guard. As the leading vendor for federal medical procurement through DLA's Medical Supply Chain, the company maintains a diverse portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 9/8/25 |